MADRIGAL PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 11.35 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 6.00K shares, a 49.76% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 5.35K shares, a 409.81% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 3.01K shares, a 156.44% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 4.31K shares, a 49.58% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 12.37K shares, a 82.26% decline from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 69.71K shares, a 3.18% decline from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 72.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 6.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 11.35K shares 10-Q · filed 2026-07-30 | 14.36K shares derived: sum of 3 quarters · filed 2026-07-30 | 18.66K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 5.35K shares 10-Q · filed 2026-05-06 | 8.36K shares derived: sum of 2 quarters · filed 2026-05-06 | 12.67K shares derived: sum of 3 quarters · filed 2026-05-06 | 16.67K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 3.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | 7.31K shares derived: sum of 2 quarters · filed 2026-02-19 | 11.32K shares derived: sum of 3 quarters · filed 2026-02-19 | 12.37K shares 10-K · filed 2026-02-19 |
| 2025-09-30 | 4.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 8.31K shares derived: sum of 2 quarters · filed 2025-11-04 | 9.36K shares 10-Q · filed 2025-11-04 | 10.53K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 4.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 5.05K shares 10-Q · filed 2025-08-05 | 6.23K shares derived: sum of 3 quarters · filed 2025-08-05 | 14.77K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 1.05K shares 10-Q · filed 2025-05-01 | 2.22K shares derived: sum of 2 quarters · filed 2025-05-01 | 10.76K shares derived: sum of 3 quarters · filed 2025-05-01 | 56.01K shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 1.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 9.71K shares derived: sum of 2 quarters · filed 2025-02-26 | 54.96K shares derived: sum of 3 quarters · filed 2025-02-26 | 69.71K shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 8.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | 53.78K shares derived: sum of 2 quarters · filed 2024-10-31 | 68.53K shares 10-Q · filed 2024-10-31 | |
| 2024-06-30 | 45.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 59.99K shares 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | 14.75K shares 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | 72.00K shares 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |